CompletedPhase 3NCT04845399
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhengzhou Gensciences Inc
- Principal Investigator
- Renchi YangInstitute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
- Intervention
- Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection(drug)
- Enrollment
- 101 target
- Eligibility
- 12 years · MALE
- Timeline
- 2021 – 2021
Study locations (16)
- Anhui Provincial Hospital, Hefei, Anhui, China
- Capital Medical University affiliated Beijing Children's Hospital, Beijing, Beijing Municipality, China
- Chongqing Three Gorges Central Hospital, Chongqing, Chongqing Municipality, China
- The First Hospital of Lanzhou University, Lanzhou, Gansu, China
- The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangzhou, China
- Nanfang Hospital of Southern Medical University, Guangzhou, Guangzhou, China
- The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
- Henan provincial People's Hospital, Zhengzhou, He'nan, China
- Henan Cancer Hospital, Zhengzhou, He'nan, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
- Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China
- Jinan central hospital, Ji'nan, Shandong, China
- The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
- +1 more locations on ClinicalTrials.gov
Collaborators
Jiangsu Gensciences lnc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04845399 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota